Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 13Phase NA 7Phase 1/2 4Phase 2/3 2Phase 4 1

Status

Completed 1318Terminated 727Active not recruiting 83Unknown 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Plasmablastic Lymphoma 1Pathologic Complete Response 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

prednylidene 1pomalidomide 1merphos 1ixazomib 1deltacortene 1aumolertinib 1Vincristine 1Rituximab 1Prednisone 1Methotrexate 1Hydrocortisone 1Etoposide 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Has results × Clear all
NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Duke University

Phase 1/2 Unknown
56 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT02981108 2023-01-23

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1/2 Unknown
364 enrolled 29 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01520558 2017-06-29

CNDO-109-AANK for AML in First Complete Remission (CR1)

Coronado Biosciences, Inc.

Phase 1/2 Unknown
12 enrolled 11 charts
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡